HiRO and CluePoints Partnership Offers RBQM Opportunities in China
Harvest Integrated Research Organization (HiRO), a Shanghai-based Clinical Research Organization, has collaborated with CluePoints, to provide Risk-Based Quality Management (RBQM) expertise and technology in the Chinese region. This partnership will increase clinical trial efficiency and reduce deviation and bias to obtain accurate patient outcomes.
CluePoints' cloud-based products are deployed to support traditional on-site monitoring, medical review, and quality to drive an RBQM approach to study execution and ultimately achieve ICH E6 (R2) compliance.
The US Food and Drug Administration is also currently working with CluePoints as part of a cooperative research and development agreement (CRADA) to utilize CSM technology to inform the site inspection process and develop advanced statistical tests to identify moderators of treatment effect and analyze real-world evidence.
HiRO and CluePoints Partnership Offers RBQM Opportunities in China
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
